Back to School: How biopharma can reboot drug development. Access exclusive analysis here

RheothRx Injection data

The Norcross, Ga., company presented Phase II data from 144 patients at the American College of Cardiology

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE